NASDAQ:AVIR Atea Pharmaceuticals Q3 2026 Earnings Date & Estimates $4.63 -0.35 (-7.03%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.00 (+0.11%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Atea Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Atea Pharmaceuticals in Q3 2026Atea Pharmaceuticals is expected to post earnings of -$0.51 per share on revenue of $50.45 million. In the same quarter a year earlier Atea Pharmaceuticals reported -$0.53 per share. Atea Pharmaceuticals last reported on August 12, 2026, posting -$0.41 per share and beating the -$0.5550 consensus estimate. Atea Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.51Expected Revenue$50.45 millionPrior-Year EPS-$0.53Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.41 (Beat by +$0.1450)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Atea Pharmaceuticals Q3 2026 Earnings FAQ When does Atea Pharmaceuticals report Q3 2026 earnings? Atea Pharmaceuticals (NASDAQ:AVIR) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Atea Pharmaceuticals' Q3 2026 earnings call? Atea Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Atea Pharmaceuticals? Analysts expect Atea Pharmaceuticals to post earnings of -$0.51 per share for Q3 2026. How much revenue is Atea Pharmaceuticals expected to report? The consensus revenue estimate for Atea Pharmaceuticals is $50.45 million for Q3 2026. Atea Pharmaceuticals Earnings HeadlinesAtea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comAtea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 8, 2026 | globenewswire.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)Atea (AVIR) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | finance.yahoo.comAtea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | seekingalpha.comSee More Atea Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atea Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your email. Email Address About Atea PharmaceuticalsAtea Pharmaceuticals (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral infections. The company’s research centers on small-molecule therapies designed to interfere with viral replication, with the goal of addressing diseases for which convenient and effective oral treatment options are needed. Atea’s lead investigational product is bemnifosbuvir, an oral nucleotide polymerase inhibitor developed for the treatment of COVID-19. The company has also pursued antiviral candidates for other infectious diseases, including hepatitis C and dengue. Atea previously entered into a collaboration with Roche to develop bemnifosbuvir for COVID-19, but the collaboration ended in 2022, returning development rights to Atea. Founded in 2012 and headquartered in Boston, Massachusetts, Atea conducts its research and development activities primarily in the United States. As a clinical-stage company, its products remain subject to clinical testing and regulatory review and are not necessarily approved or commercially available in all targeted markets.View Atea Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
